Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

721. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure.

Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. 18946063 2008 10 23 2008 10 30 2008 10 23 1533-4406 359 17 2008 Oct 23 The New England journal of medicine N. Engl. J. Med. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. 1778-85 10.1056/NEJMoa0708234 Pulmonary-vein isolation is increasingly being used to treat atrial fibrillation in patients with heart failure. In this prospective, multicenter clinical trial, we randomly assigned (...) patients with symptomatic, drug-resistant atrial fibrillation, an ejection fraction of 40% or less, and New York Heart Association class II or III heart failure to undergo either pulmonary-vein isolation or atrioventricular-node ablation with biventricular pacing. All patients completed the Minnesota Living with Heart Failure questionnaire (scores range from 0 to 105, with a higher score indicating a worse quality of life) and underwent echocardiography and a 6-minute walk test (the composite primary

NEJM2008

722. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. BACKGROUND: Atrial fibrillation (AF) is the most frequent sustained arrhythmia. After restoration of normal sinus rhythm, the recurrence rate of AF is high. Antiarrhythmic drugs have been widely used to prevent recurrence, but the effect of these drugs on mortality and other clinical outcomes is unclear. OBJECTIVES: To determine, in patients who recovered sinus rhythm after AF, the effect of long-term (...) treatment with antiarrhythmic drugs on death, stroke and embolism, adverse effects, pro-arrhythmia and recurrence of AF. If several antiarrhythmics were effective our secondary aim was to compare them. SEARCH STRATEGY: The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Libary (Issue 2, 2005), MEDLINE (1950 to May 2005) and EMBASE (1966 to May 2005) were searched. The reference lists of retrieved articles, recent reviews and meta-analyses were checked. No language restrictions

Cochrane2007

723. Management of atrial fibrillation.

Management of atrial fibrillation. Atrial fibrillation is the most common sustained cardiac rhythm disorder, and confers a substantial mortality and morbidity from stroke, thromboembolism, heart failure, and impaired quality of life. With the increasingly elderly population in the developed world, as well as improvements in the management of myocardial infarction and heart failure, the prevalence of atrial fibrillation is increasing, resulting in a major public-health problem. This Review aims (...) to provide an overview on the modern management of atrial fibrillation, with particular emphasis on pharmacological and non-pharmacological approaches. Irrespective of a rate-control or rhythm-control strategy, stroke prevention with appropriate thromboprophylaxis still remains central to the management of this common arrhythmia. Electrophysiological approaches could hold some promise for a curative approach in atrial fibrillation.

Lancet2007

724. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. BACKGROUND: Non-valvular atrial fibrillation (AF) carries an increased risk of stroke mediated by embolism of stasis-precipitated thrombi originating in the left atrial appendage. Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events (...) , but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio-embolic mechanism of most strokes in AF patients. OBJECTIVES: To characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or transient ischemic attack (TIA). SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (June

Cochrane2007

725. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use. OBJECTIVES: To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated (...) for prevention of thromboembolism in AF. SEARCH STRATEGY: Articles were identified through the Cochrane Collaboration's CENTRAL database and MEDLINE until December 1999. SELECTION CRITERIA: Included Randomized controlled trials of drugs to prevent thromboembolism in adults with non-postoperative AF. Excluded RCTS of patients with rheumatic valvular disease. DATA COLLECTION AND ANALYSIS: Data were abstracted by two reviewers. Odds ratios from all qualitatively similar studies were combined, with weighting

Cochrane2007

726. Negative D-dimer may allow safe early cardioversion of atrial fibrillation

Negative D-dimer may allow safe early cardioversion of atrial fibrillation BestBets: Negative D-dimer may allow safe early cardioversion of atrial fibrillation Negative D-dimer may allow safe early cardioversion of atrial fibrillation Report By: Richard Body - Specialist Registrar Search checked by Babak Allie - Specialist Registrar Institution: Manchester Royal Infirmary Date Submitted: 30th August 2005 Date Completed: 29th May 2007 Last Modified: 19th April 2007 Status: Green (complete) Three (...) Part Question In [patients with atrial fibrillation being considered for electrical or pharmacologic cardioversion] does [measurement of D-dimer] allow [exclusion of atrial thrombus]? Clinical Scenario A 45 year-old man presents to the Emergency Department with a 48-hour history of palpitations, postural light-headedness and exertional dyspnoea. ECG demonstrates atrial fibrillation (AF) at a rate of 130 beats/minute. There are no apparent reversible causes following history, examination, chest

BestBETS2007

727. Pulse pressure and risk of new-onset atrial fibrillation.

Pulse pressure and risk of new-onset atrial fibrillation. CONTEXT: Atrial fibrillation (AF) is responsible for considerable morbidity and mortality, making identification of modifiable risk factors a priority. Increased pulse pressure, a reflection of aortic stiffness, increases cardiac load and may increase AF risk. OBJECTIVE: To examine relations between pulse pressure and incident AF. DESIGN, SETTING, AND PARTICIPANTS: Prospective, community-based observational cohort in Framingham, Mass (...) , including 5331 Framingham Heart Study participants aged 35 years and older and initially free from AF (median age, 57 years; 55% women). MAIN OUTCOME MEASURES: Incident AF. RESULTS: AF developed in 698 participants (13.1%) a median of 12 years after pulse pressure assessment. Cumulative 20-year AF incidence rates were 5.6% for pulse pressure of 40 mm Hg or less (25th percentile) and 23.3% for pulse pressure greater than 61 mm Hg (75th percentile). In models adjusted for age, sex, baseline and time

JAMA2007

728. Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation

Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Article Text Therapeutics Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you

Evidence-Based Medicine (Requires free registration)2007

729. Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation

Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Article Text Therapeutics Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2007

730. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Nasr I A, Bouzamondo A, Hulot J S, Dubourg O, Le Heuzey J Y, Lechat P CRD summary This review concluded that beta-blocker administration appears to effectively reduce the incidence (...) of atrial fibrillation in patients with systolic heart failure. The authors’ conclusions appear supported by the evidence presented, but without details of the methodological quality of the studies it is difficult to assess their reliability. Authors' objectives To evaluate the effect of beta-blocker administration on the incidence of atrial fibrillation (AF) in patients with congestive heart failure (HF). Searching PubMed and the Cochrane CENTRAL Register were searched; the search terms were reported. Only studies

DARE.2007

731. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation

Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Buckley M S, Nolan P E, Slack M K, Tisdale J E, Hilleman D E, Copeland J G CRD summary This review concluded that total (...) amiodarone doses of 3,000 mg or higher may be more effective than lower doses in reducing the rate of post-operative atrial fibrillation after cardiac surgery. Pre-operative initiation of amiodarone appears to be unnecessary. Given the potential weaknesses in the review methods and analyses, it is difficult to assess the robustness of the authors' conclusions. Authors' objectives To assess optimal dosing regimens of prophylactic amiodarone for reducing the incidence of atrial fibrillation (AF) after

DARE.2007

732. An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation Leigh J P, White R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of warfarin versus a second anticoagulant in hypothetical cohort of 70-year-old patients with atrial fibrillation. There was substantial variation in rates and costs of adverse events when considering all possible scenarios, but the difference in costs between the two drugs was modest. Overall, the analysis

NHS Economic Evaluation Database.2007

733. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation

The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation Pietrasik A, Kosior D A, Niewada M, Opolski G, Latek M, Kaminski B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors compared sinus rhythm (SR) restoration and maintenance against ventricular rate control supported by thromboembolic prophylaxis in persistent atrial fibrillation (AF). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with the first clinically overt

NHS Economic Evaluation Database.2007

734. A health economic evaluation of concomitant surgical ablation for atrial fibrillation

A health economic evaluation of concomitant surgical ablation for atrial fibrillation A health economic evaluation of concomitant surgical ablation for atrial fibrillation A health economic evaluation of concomitant surgical ablation for atrial fibrillation Lamotte M, Annemans L, Bridgewater B, Kendall S, Siebert M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness, for patients with atrial fibrillation, undergoing cardiac surgery, of high-intensity focused ultrasound-assisted surgical ablation, the classic ‘cut and sew’ maze procedure, and subsequent percutaneous ablation, in comparison with drug treatment. The maze procedure or surgical ablation were highly cost-effective

NHS Economic Evaluation Database.2007

735. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis

Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Ho K M, Sheridan D J, Paterson T CRD summary This well-conducted review found that intravenous magnesium is not effective in converting acute onset atrial fibrillation to sinus rhythm in patients with a normal serum magnesium (...) concentration. The addition of intravenous magnesium to digoxin reduces fast ventricular response rates, but is less effective than other calcium antagonists or amiodarone. These findings are likely to be reliable. Authors' objectives To determine the effectiveness of intravenous magnesium in the conversion of acute onset atrial fibrillation (AF) to sinus rhythm, and in reducing ventricular response and risk of bradycardia. Searching The Cochrane CENTRAL Register, EMBASE and MEDLINE were searched to May

DARE.2007

736. Management and Consequences of Atrial Fibrillation

Management and Consequences of Atrial Fibrillation Management and Consequences of Atrial Fibrillation | Clinical Correlations Management and Consequences of Atrial Fibrillation August 2, 2007 Commentary by Timothy Wong, MD A group of short articles focusing on the consequences and management of atrial fibrillation (AF) recently appeared in the July 7th issue of the Health section of the . In brief, the articles highlighted the risks of thromboembolism, the lack of very successful medical (...) therapies, and the growing demand for catheter-based atrial fibrillation ablation procedures. As a cardiology fellow on the consultation service at a teaching hospital in western Pennsylvania, I find that atrial fibrillation is perhaps the most common reason for consultation. I would like to share a brief overview of an approach to atrial fibrillation management and also clarify some points discussed by the articles. There are several questions that should be answered when seeing a patient

Clinical Correlations2007

737. Vagally-induced Atrial Fibrillation

Vagally-induced Atrial Fibrillation Vagally-induced Atrial Fibrillation | Clinical Correlations Vagally-induced Atrial Fibrillation November 7, 2007 Case by: Alana Choy-Shan, Chief Resident Commentary by William Slater MD, Associate Professor of Medicine, Division of Cardiology Following Thanksgiving dinner, a 36 year-old healthy man developed palpitations and heart racing. He was evaluated in the emergency room and was noted to be in atrial fibrillation with rapid ventricular response. All (...) atrial fibrillation? 2. How should he be treated if another episode occurs? 3. Is there anything he can do to prevent a recurrence? Patients with “lone AF’, i.e. those without structural heart disease nor a history of hypertension, often get their paroxysms of AF in settings of autonomic fluctuation. Clinicians often easily recognize adrenergic triggers (exercise, emotional stress, alcohol or caffeine) but less commonly are aware that vagal excess is often a common trigger for lone AF. The development of AF in

Clinical Correlations2007

738. Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care

Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. Article Text Therapeutics Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. Free Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2007

739. Atrial Fibrillation Part 2: Additional Words of Wisdom

Atrial Fibrillation Part 2: Additional Words of Wisdom Atrial Fibrillation Part 2: Additional Words of Wisdom | Clinical Correlations Atrial Fibrillation Part 2: Additional Words of Wisdom August 3, 2007 Commentary by William Slater, MD Associate Professor of Medicine, Divsion of Cardiology The vast majority of patients with persistent AF can be rendered asymptomatic with AV nodal blocking drugs and don’t require ablation. Digitalis is underused but is often of major benefit, either alone (...) terminate occasional PAF episodes and make ablation unnecessary. Remember that upwards of 20% of ablations for AF result in the creation of a new arrhythmia (an intra-atrial tachycardia) requiring a second procedure, which is not always curative. Ablation is still an evolving technique, and is not appropriate for the majority of atrial fibrillators. The AFFIRM and RACE studies confirmed that by an “intention to treat” analysis, older patients in AF are just as well treated with a rate control strategy

Clinical Correlations2007

740. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.

Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. 17426275 2007 04 11 2007 04 16 2016 10 17 1538-3598 297 14 2007 Apr 11 JAMA JAMA Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. 1562-7 Atrial fibrillation (AF) is the most common arrhythmia to occur after cardiac surgery. An exaggerated inflammatory response has been proposed to be one etiological factor. To test whether (...) intravenous corticosteroid administration after cardiac surgery prevents AF after cardiac surgery. A double-blind, randomized multicenter trial (study enrollment August 2005-June 2006) in 3 university hospitals in Finland of 241 consecutive patients without prior AF or flutter and scheduled to undergo first on-pump coronary artery bypass graft (CABG) surgery, aortic valve replacement, or combined CABG surgery and aortic valve replacement. Patients were randomized to receive either 100-mg hydrocortisone

JAMA2007